Profile data is unavailable for this security.
About the company
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage bio-pharmaceutical company. The Company is in the business of research and development (R&D) of pharmaceutical products to unmet medical needs in the areas of oncology, neurodegeneration and immunology. The Company develops New Chemical Entities (NCE), New Biological Entities and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its Novel Drug Delivery Systems (NDDS) include Wrap Matrix Technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology is useful to develop controlled release tablets. It has developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. It has also developed Xelpros, a BAK free latanoprost eye drop developed using Lipexelle technology. Xelpros is commercialized by its partner in the United States. It has also developed PDP-716 eye drops for treatment of Glaucoma based on its TearAct technology.
- Revenue in INR (TTM)1.07bn
- Net income in INR-3.63bn
- Incorporated2006
- Employees407.00
- LocationSun Pharma Advanced Research Co Ltd17B Mahal Industrial EstateMahakali Caves Road, Andheri (East)MUMBAI 400093IndiaIND
- Phone+91 2 266455685
- Fax+91 2 266455685
- Websitehttps://www.sparc.life/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aarti Pharmalabs Ltd | 18.32bn | 1.95bn | 48.20bn | 1.40k | 24.77 | -- | 18.22 | 2.63 | 21.47 | 21.47 | 202.17 | -- | -- | -- | -- | 13,085,090.00 | -- | -- | -- | -- | 42.00 | -- | 10.62 | -- | -- | 16.14 | -- | -- | 62.11 | -- | 58.27 | -- | -- | -- |
| Shilpa Medicare Ltd | 11.23bn | -6.71m | 51.92bn | 1.03k | -- | -- | 48.83 | 4.62 | -0.0714 | -0.0714 | 131.44 | -- | -- | -- | -- | 10,873,050.00 | -- | 3.89 | -- | 4.92 | 64.42 | 60.22 | -0.0538 | 9.29 | -- | 1.16 | -- | 10.65 | -8.33 | 5.82 | -153.54 | -- | 14.58 | -- |
| Orchid Pharma Ltd | 8.12bn | 1.25bn | 55.41bn | 838.00 | 38.33 | -- | 34.86 | 6.82 | 28.50 | 26.84 | 175.33 | -- | -- | -- | -- | 9,691,729.00 | -- | -1.07 | -- | -1.96 | 41.49 | 45.87 | 15.63 | -3.52 | -- | 4.34 | -- | -- | 19.00 | -0.6456 | 187.87 | -- | 68.72 | -- |
| Blue Jet Healthcare Ltd | -100.00bn | -100.00bn | 67.96bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.49 | -- | -11.88 | -- | -- | -- |
| F D C Ltd | 19.16bn | 2.90bn | 74.40bn | 6.37k | 25.93 | -- | 22.64 | 3.88 | 17.63 | 17.63 | 116.59 | -- | -- | -- | -- | 3,006,457.00 | -- | 11.68 | -- | 13.29 | 65.72 | 62.03 | 15.11 | 15.85 | -- | 70.61 | -- | 1.22 | 16.74 | 10.49 | -10.34 | 2.26 | 25.03 | -- |
| Marksans Pharma Ltd | 21.03bn | 3.17bn | 75.75bn | 1.40k | 23.71 | -- | 19.57 | 3.60 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
| Procter & Gamble Health Ltd | 12.37bn | 2.27bn | 78.36bn | 1.41k | 34.57 | 9.72 | 31.04 | 6.33 | 136.55 | 136.55 | 745.23 | 485.49 | 1.15 | 2.51 | 10.40 | 8,791,756.00 | 21.02 | -- | 27.67 | -- | 69.97 | -- | 18.32 | -- | 2.79 | 383.03 | 0.0132 | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Strides Pharma Science Ltd | 39.53bn | -1.52bn | 81.19bn | 2.85k | -- | -- | 137.25 | 2.05 | -16.88 | -10.96 | 436.72 | -- | -- | -- | -- | 13,871,790.00 | -- | -0.9448 | -- | -1.59 | 58.90 | 49.75 | -4.37 | -2.19 | -- | 0.9061 | -- | -- | 20.13 | 5.33 | 51.93 | -- | -25.10 | -5.59 |
| Wockhardt Ltd | 27.76bn | -5.01bn | 87.54bn | 2.74k | -- | -- | -- | 3.15 | -34.79 | -34.79 | 192.79 | -- | -- | -- | -- | 10,131,390.00 | -- | -4.12 | -- | -7.34 | 57.60 | 53.98 | -19.16 | -10.98 | -- | -0.1981 | -- | -- | -17.93 | -7.60 | -129.10 | -- | -7.43 | -- |
| Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 87.91bn | 407.00 | -- | -- | -- | 82.41 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
| Neuland Laboratories Ltd. | 15.81bn | 3.17bn | 90.99bn | 1.57k | 28.70 | -- | 24.34 | 5.76 | 247.14 | 247.14 | 1,232.07 | -- | -- | -- | -- | 10,048,590.00 | -- | 5.69 | -- | 7.95 | 51.76 | 43.56 | 20.06 | 8.07 | -- | 28.54 | -- | 8.27 | 25.25 | 17.62 | 156.21 | 68.43 | -13.12 | -- |
| Glenmark Life Sciences Ltd | 23.68bn | 5.19bn | 91.96bn | 1.82k | 17.72 | -- | 16.14 | 3.88 | 42.36 | 42.36 | 193.15 | -- | -- | -- | -- | 12,982,110.00 | -- | -- | -- | -- | 55.92 | -- | 21.93 | -- | -- | 538.47 | -- | -- | 1.79 | -- | 11.52 | -- | -- | -- |
| Granules India Ltd | 45.26bn | 3.95bn | 101.30bn | 3.65k | 25.62 | -- | 16.94 | 2.24 | 16.32 | 16.32 | 186.88 | -- | -- | -- | -- | 12,400,240.00 | -- | 11.15 | -- | 16.55 | 51.94 | 49.35 | 8.73 | 12.39 | -- | 6.53 | -- | 10.08 | 19.84 | 21.67 | 25.16 | 31.26 | -1.66 | 8.45 |
| Caplin Point Laboratories Ltd | 16.30bn | 4.38bn | 103.06bn | 777.00 | 23.67 | -- | 21.05 | 6.32 | 57.33 | 57.33 | 213.53 | -- | -- | -- | -- | 20,980,180.00 | -- | 21.04 | -- | 24.25 | 56.48 | 52.84 | 27.08 | 25.02 | -- | 845.56 | -- | 9.37 | 15.54 | 22.13 | 25.49 | 21.05 | 31.87 | 17.61 |
| Jubilant Pharmova Ltd | 66.22bn | 378.60m | 107.33bn | 1.03k | 279.72 | -- | 18.31 | 1.62 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
| Eris Lifesciences Ltd | 18.61bn | 3.86bn | 120.21bn | 3.55k | 31.15 | -- | 22.15 | 6.46 | 28.36 | 28.36 | 136.57 | -- | -- | -- | -- | 5,245,254.00 | -- | 17.62 | -- | 20.12 | 82.02 | 80.57 | 20.36 | 27.34 | -- | 7.94 | -- | -- | 25.10 | 14.52 | -5.90 | 5.38 | 101.87 | -- |
Data as of Apr 26 2024. Currency figures normalised to Sun Pharma Advanced Research Co Ltd's reporting currency: Indian Rupee INR
1.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 2.35m | 0.72% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 1.72m | 0.53% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 620.84k | 0.19% |
| quant Money Managers Ltd.as of 31 Mar 2024 | 595.87k | 0.18% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 425.63k | 0.13% |
| BlackRock Advisors (UK) Ltd.as of 02 Apr 2024 | 361.64k | 0.11% |
| TIAA-CREF Investment Management LLCas of 29 Feb 2024 | 60.59k | 0.02% |
| ITI Asset Management Ltd. (India)as of 31 Mar 2024 | 58.63k | 0.02% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Mar 2024 | 56.26k | 0.02% |
| State Street Global Advisors Ltd.as of 04 Apr 2024 | 36.34k | 0.01% |
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
